Galena Biopharma Inc (NASDAQ:GALE) a biopharmaceutical firm committed to the advancement and commercialization of hematology as well as oncology therapeutics issued the report from a meeting of the DSMB for the two IST combination clinical studies with NeuVax™ plus trastuzumab. The studies are being carried out in breast cancer...
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) recently announced that it would be exercising a 1-for-10 reverse stock split, of all outstanding shares of the company’s common stock. Moreover, RNN would also exercise a corresponding proportional reduction in the number of authorized capital shares of the company, as well. The action is...
Before we go into details of Delcath Systems, Inc. (NASDAQ:DCTH), a biotech company that needs your immediate attention is OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP). OBMP is a clinical stage biopharmaceutical company that develops cancer immunotherapy products. The company has proprietary rights to a breast and prostate patent vaccine; and a process...
Dallas, Texas 09/16/2013 (Financialstrend) - In a research note that was issued on Thursday, Needham & Company weighed on Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) stock. They have assigned a “buy” rating on the stock and a price-target of $8.00. This price-target is an indication that there is a potential upside...
The stock price of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) are moving north on the chart since last few days. Recent NASH play has finally rewarded firm’s shareholders. The biotech concern has made a transformational collaboration agreement with drug giant company Novartis AG (ADR)(NYSE:NVS) about its compound emricasan. The biotech industry continues...
We are going to take a close look at () today to get a better sense of the company and its current status, as well as the opportunity it may offer for prospective investors. Today's focus will be a fundamental evaluation of the stock from top to bottom. As...
Vancouver, British Columbia, Canada – April 17, 2018 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQB:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, announced that...
May 06, 2015 OTC Disclosure & News Service - SILVER SPRING, Md., May 6, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the Institute of Virology at the...
AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a...
We are going to take a close look at () today to get a better sense of the company and its current status, as well as the opportunity it may offer for prospective investors. Today's focus will be a fundamental evaluation of the stock from top to bottom. As...